Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice

RT @DiabetologiaJnl: Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy (low-dose CD3 antibodies) to improve…

Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy (low-dose CD3 antibodies) to improve pancreatic beta cell survival & metabolic function and induce stable remission of recent-onset type 1 diabetes in NOD mice https://t.c

RT @DiabetologiaJnl: Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy (low-dose CD3 antibodies) to improve…

RT @DiabetologiaJnl: Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy (low-dose CD3 antibodies) to improve…

Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy (low-dose CD3 antibodies) to improve pancreatic beta cell survival & metabolic function and induce stable remission of recent-onset type 1 diabetes in NOD mice https://t.c